Human papillomavirus 16/18 vaccine recombinant bivalent (Xiamen Innovax)

重组人乳头瘤病毒16/18型双价疫苗（厦门万泰沧海）

Report date: 2022/10/17 15:14:42

Base Information

Drug NameHuman papillomavirus 16/18 vaccine recombinant bivalent (Xiamen Innovax)
Drug Alias Name重组人乳头瘤病毒16/18型双价疫苗Human papillomavirus 16/18 vaccineHuman papillomavirus 16/18 bivalent vaccine - Xiamen双价人乳头瘤病毒疫苗(大肠杆菌)馨可宁 +[6] 
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Vaccine type > Multivalent vaccineVaccines > Biological material > Viral vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsVulvar NeoplasmsVaginal NeoplasmsUterine Cervical Neoplasms +[7] 
Global Approved IndicationsUterine Cervical NeoplasmsPapillomavirus Infections
Approved Indications in ChinaUterine Cervical NeoplasmsPapillomavirus Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2019/12/30
Country/TerritoryThailandNepalBangladesh +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesXiamen Innovax Biotech Co LtdBeijing Wantai Biological Pharmacy Enterprise Co LtdXiamen University
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXiamen Innovax Biotech Co Ltd
Inactive CompaniesXiamen UniversityBeijing Wantai Biological Pharmacy Enterprise Co Ltd
Active IndicationsUterine Cervical NeoplasmsPapillomavirus Infections
Inactive IndicationsVulvar NeoplasmsVaginal NeoplasmsCervical Intraepithelial Neoplasia +[5] 

Other Information

ATC CodeJ07BM02
Related LinksN/A